Rimantadine

Rimantadine (1-Rimantadine) is an orally active inhibitor for M2 protein, which blocks the hydrogen ion channel activity, prevents the entry and replication of the virus, and exhibits board-spectrum antiviral activity. Rimantadine significantly inhibits hepatitis A virus (HAV) replication at the post-entry stage in Huh7 cells. Rimantadine enhances autophagy. Rimantadine has a significant protective effect against H3N2 virus in mouse model^[1][2]. In Vitro:Rimantadine (0-10 μg/mL, 72 h) inhibits the HAV subgenomic replicon and HAV replication in Huh7 and IHH cells infected with HAV HA11-1299 genotype IIIA^[1].
Rimantadine (0-10 μg/mL, 48 h) significantly inhibits HAV HM175 genotype IB subgenomic replicon replication dose-dependently in HuhT7 cells^[1].
Rimantadine (10 μg/mL, 1 h) significantly inhibits HAV HA11-1299 genotype IIA replication at the post-entry stage in Huh7 cells^[1].
Rimantadine (10 μg/mL, 48 h) enhances the expression of LC3, increases the number of lysosomes, and stimulates the fusion of lysosomes and autophagosomes in Huh7 cells^[1]. In Vivo:Rimantadine (5-20 mg/kg/day, p.o., twice daily for 5 d) prolongs survival of ICR mice infected with influenza A (H3N2) virus in combination with Oseltamivir (HY-13317)^[2].
Rimantadine (5-10 mg/kg/day, p.o., twice daily for 5 d) reduces the lung viral titers of ICR mice infected with influenza A (H3N2) virus in combination with Oseltamivir^[2].